missing translation for 'onlineSavingsMsg'
Läs mer
Läs mer
Dihydroergotamine mesylate, Tocris Bioscience™

Beskrivning
Dihydroergotamine mesylate is a partial α-adrenergic agonist. Partial D2 dopaminergic receptor agonist. Competitive 5-HT antagonist.
Specifikationer
Specifikationer
| Kemiskt namn eller material | Dihydroergotamine mesylate |
| CAS | 6190-39-2 |
| Molekylformel | C34H41N5O8S |
| MDL-nummer | MFCD00058615 |
| Kvantitet | 100 mg |
| Synonym | dihydroergotamine mesylate, dihydroergotamine methanesulfonate salt, dihydroergotoxine, prestwick_746, dihydroergotamine methanesulfonate salt, powder, dihydroergotamine mesilate, european pharmacopoeia ep reference standard, dihydroergotamine for peak identification, european pharmacopoeia ep reference standard, dihydroergotamine mesylate, united states pharmacopeia usp reference standard, 4r,7r-n-1s,2s,4r,7s-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo 7.3.0.0^ 2,6 dodecan-4-yl-6-methyl-6,11-diazatetracyclo 7.6.1.0^ 2,7 .0^ 12,16 hexadeca-1 15 ,9,12 16 ,13-tetraene-4-carboxamide; methanesulfonic acid, 6ar,9r-n-2r,5s,10as,10bs-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8h-oxazolo 3,2-a pyrrolo 2,1-c pyrazin-2-yl-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo 4,3-fg quinoline-9-carboxamide methanesulfonate |
| InChI-nyckel | ADYPXRFPBQGGAH-UMYZUSPBSA-N |
| LEDER | CS(O)(=O)=O.CN1C[C@@H](C[C@H]2[C@H]1CC1=CNC3=CC=CC2=C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3=CC=CC=C3)N2C1=O |
| IUPAC-namn | (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid |
| Molekylvikt (g/mol) | 679.79 |
| Visa mer |
Produkttitel
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.
Hittar du en möjlighet till förbättring?